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Abstract
Purpose of Review In recent years, a vast body of evidence has accumulated indicating the role of the immune system in the
regulation of blood pressure and modulation of hypertensive pathology. Numerous cells of the immune system, both innate and
adaptive immunity, have been indicated to play an important role in the development and maintenance of hypertension. The
purpose of this review was to summarize the role of adaptive immunity in experimental models of hypertension (genetic, salt-
sensitive, and Angiotensin (Ang) II induced) and in human studies. In particular, the role of T and B cells is discussed.
Recent Findings In response to hypertensive stimuli such as Ang II and high salt, T cells become pro-inflammatory and they
infiltrate the brain, blood vessel adventitia and periadventitial fat, heart, and the kidney. Pro-inflammatory T cell–derived
cytokines such as IFN-γ and TNF-α (from CD8+ and CD4+Th1) and IL-17A (from the γδ-T cell and CD4+Th17) exacerbate
hypertensive responses mediating both endothelial dysfunction and cardiac, renal, and neurodegenerative injury. The modulation
of adaptive immune activation in hypertension has been attributed to target organ oxidative stress that leads to the generation of
neoantigens, including isolevuglandin-modified proteins. The role of adaptive immunity is sex-specific with much more pro-
nounced mechanisms in males than that in females. Hypertension is also associated with B cell activation and production of
autoantibodies (anti-Hsp70, anti-Hsp65, anti-Hsp60, anti-AT1R, anti-α1AR, and anti-β1AR). The hypertensive responses can be
inhibited by T regulatory lymphocytes (Tregs) and their anti-inflammatory IL-10.
Summary Adaptive immunity and its interface with innate mechanisms may represent valuable targets in the modulation of
blood pressure, as well as hypertension-related residual risk.
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Introduction
In recent years, accumulating evidence indicates the role of
the immune system in the regulation of blood pressure and
cardiovascular risk linked to hypertension. While our initial
studies using RAG1−/−mice have shown the pathogenetic role
of T cells in this process, subsequent cooperation of numerous
cells of the immune system, both innate and adaptive immu-
nity, has been implicated in the development and maintenance
of hypertension (Fig. 1) [1••, 2–7]. The first line of defense
includes the innate response and takes place relatively very
fast. The second line of the defense, namely adaptive immu-
nity, is characterized by a delayed but very targeted response.
In terms of the development of hypertension, the interaction
between these two components of the immune system seems
to be essential [8, 9••].
Innate-Adaptive Immunity Interface in Initiation
of Inflammation
Innate cells, such as granulocytes, monocytes, macrophages,
and dendritic cells, express the pathogen recognition receptors
(PRRs; such as Toll-like receptors (TLRs)), and they can rec-
ognize pathogen-associated molecular patterns (PAMPs) or
damage-associated molecular patterns (DAMPs). A number
of molecules, of importance to hypertension, may act as
DAMPs activating Toll-like receptors. These include nuclear
or cytosolic proteins as well as neoantigens [10]. The latter
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represent forms of “new antigens” arise in the stress condition,
and they are generated, for example in the context of hyper-
tension, during oxidative stress or they are then released from
injured tissue [11]. These molecules, acting as DAMPS, may
activate innate immunity, mainly through interaction with
Toll-like receptors (TLRs) or may also be presented by
antigen-presenting cells (APC) in the context of major histo-
compatibility complex II (MHC II) initiating adaptive immu-
nity leading to the activation of T and B lymphocytes [12,
13••]. In classical immunology, the key role of the adaptive
immunity is to create memory cells that recognize these spe-
cific antigens during the re-appearance in the environment [3,
14, 15]. In the future, due to the presence of memory T cells,
the response is faster and more effective [16]. In hypertension,
indeed, the accumulation of memory cells has been described
in both animal models [17] and humans [3].
Role of T Cells and Their Subsets in Experimental
Model of Hypertension
In many experimental models of hypertension including ge-
netic model and salt or angiotensin (Ang II)-induced model,
the key role of T cells has been demonstrated [1••, 2, 3].
Initial reports used a genetic model of essential hyperten-
sion and revealed that spontaneously hypertensive rats (SHRs)
had reduced numbers of T cells in the thymus and that restor-
ing thymic function by histocompatible thymus grafts or thy-
mic extracts suppressed the development of hypertension
[18–20]. The immunological restoration was associated with
significant suppression of high blood pressure. Depression of
T cell function was accompanied by an appearance of natural
thymocytotoxic autoantibody (NTA) that was decreased after
thymus grafts or extracts [20]. Further studies demonstrated
that T cells and especially non-helper subsets were depressed
in both the prehypertensive and developmental phases of hy-
pertension in SHR [21]. Subsequent studies performed by
Rodriguez-Iturbe et al. showed that lymphocytes and macro-
phage infiltrate the kidney of SHR and that this phenomenon
is more pronounced with age. The interventions leading to the
reduction of those cells were associated with improvement of
hypertension. Six-month-old SHR showed increased content
of T helper cells and high CD4/CD8 ratio [22]. Interestingly,
hypertensive responses depend on the sex of the animals and
this impacts the T cell profile [23]. Moreover, distinct SHR
lines differ in their susceptibility to hypertensive end-organ
disease [24]. SHR-A3 is end-organ injury susceptible line
whereas SHR-B2 is not [24–26]. This phenomenon is associ-
ated with the regulation of Tregs [24–26]. SHR-A3 has an
additional hypertension locus that contributes to higher blood

















Ang II and salt hypertensive stimuliFig. 1 The role of adaptive
immunity in the development and
maintenance of hypertension. T
cells in response to Ang II and/or
high-salt stimuli become pro-
inflammatory and infiltrate the
brain, blood vessels especially
adventitia and periadventitial fat,
heart, and kidney. T cells produce
pro-inflammatory cytokines such
as IFN-γ and TNF-α (CD8+,
CD4+Th1) and IL-17A (γδ-T
cell, CD4+Th17), which
exacerbate hypertensive
responses and induce endothelial
dysfunction as well as cardiac,
renal, and neurodegenerative
injury. In hypertension, B cell and
their antibodies play the role in
end-organ damage. The
hypertensive responses are
inhibited by T regulatory cells
(Treg) and their anti-
inflammatory IL-10
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modified in genetically hypertensive rats by immunosuppres-
sive therapy using mycophenolate mofetil (MMF). After the
treatment with MMF, the systemic hypertension was blunted
which was accompanied by lymphocyte, macrophage, and
angiotensin II–positive cell reductions in the kidney. This ef-
fect was accompanied by reduced oxidative stress [27].
Mycophenolate mofetil also prevented salt-sensitive hyperten-
sion (SSHTN) in Sprague Dawley rats receiving Ang II. In
this model, kidney injury was significantly reduced by MMF
administration. This was accompanied by decreased prolifer-
ation, T cell infiltration, and activation [28•]. In Dahl salt-
sensitive (SS) rats, increasing salt consumption enlarged renal
infiltration of T lymphocytes and increased arterial blood pres-
sure and albumin excretion and resulted in renal glomerular
and tubular damage [29]. Infiltrating T cells produced Ang II
that caused renal disease. Suppression of T cell decreased
intrarenal Ang II and prevented Dahl SS hypertension [29].
Interestingly, the high-protein diet was associated with greater
numbers of infiltrating T lymphocytes in kidney and highest
mean arterial blood pressure and urine to creatinine ratio in
comparison with a low-protein diet [30]. This observation
shows that hypertension in Dahl SS rats is sensitive to both
NaCl and protein intake [30]. Viel et al. have demonstrated
that T lymphocyte contribution to vascular inflammation is
related to the influence of chromosome 2 in genetic salt-
sensitive hypertension [31]. SSBN2 rats in which chromo-
some 2 has been transferred from normotensive to hyperten-
sive animals had reduced systolic blood pressure compared
with Dahl rats. Hypertensive rats exhibited increased inflam-
matory markers and mediators especially VCAM-1, ICAM-1,
CCR5, and CD4 compared with normotensive Brown
Norway rats. SSBN2 rats revealed a reduction in all these
markers in comparison with Dahl rats. Aortic expression of
Foxp3 and transforming growth factor beta (TGF-beta) and
IL-10 were enhanced in SSBN2 rats indicating that Tregs
attenuate salt-sensitive hypertension [31]. While all these
studies were very informative, the direct proof of involvement
of T cells in hypertension was provided by our studies in mice
lacking recombination activating gene 1 (RAG1−/−), which
was then confirmed in RAG1−/− Dahl salt-sensitive rats [1••,
32]. Those animals lack mature Tand B cells in the circulation
and in the spleen, creating a unique opportunity to address the
role of these cells in hypertension. RAG1−/− mice have
blunted hypertension and did not develop vascular patholo-
gies during Ang II or deoxycorticosterone acetate (DOCA)-
salt-induced hypertension. However, the adoptive transfer of
T cells but not B lymphocytes restored these abnormalities
[1••]. The infiltration of T cells into the kidney upon high-
salt intake was blunted in RAG1−/− rats compared with the
controls. This phenomenon was accompanied by lower arte-
rial blood pressure and urinary albumin excretion [32].
Further evidence for the role of the adaptive immunity in
hypertension comes from the study of Crowley et al. [33].
They demonstrated that SCID (severe combined immunode-
ficiency) mouse strain lacking in T and B lymphocytes is
protected against Ang II–dependent hypertension. SCID mice
developed less cardiac hypertrophy and had significant reduc-
tions in heart and kidney injury following Ang II challenge.
This phenomenon was associated with the stimulation of
eNOS- and COX-2-dependent pathways [33]. In Ang II hy-
pertensive rats, Shao et al. have demonstrated T helper lym-
phocytes imbalance with an increase of Th1 and a decrease of
Th2 in the spleen and kidney. The administration of Ang II
receptor blocker (ARB) olmesartan, but not vessel dilatator
hydralazine, ameliorated the manifestations of disease and
the imbalance in T helper subsets [34]. Further mechanisms
were provided by an interesting study by Trott et al. who have
shown that CD8+ T cells are the primarily activated T lym-
phocytes in hypertension and CD8−/− mice were protected
from angiotensin-induced endothelial dysfunction and vascu-
lar remodeling in the kidney [35]. Also, double-negative T
(DN-T) cells (CD3+CD4−CD8−) are abundantly recruited to
the vasculature especially perivascular adipose tissue in Ang
II–dependent hypertension [1••, 2]. It is interesting to note that
the loss of lymphocyte adaptor protein LNK (also known as
SH2B3) exacerbates inflammation and renal and vascular dys-
function following angiotensin II–induced hypertension [36].
Recently, we provided the evidence that regulated on activa-
tion, normal T cell expressed and secreted (RANTES) chemo-
kine is essential for T cell homing in hypertension.
Angiotensin II–induced hypertension was associated with an
increase of RANTES level in perivascular adipose tissue
(PVAT). Also, the expression of CCR1, CCR3, and CCR5
was higher in T cells infiltrating PVAT upon Ang II infusion.
Moreover, RANTES−/− protects against vascular leukocyte
and especially T lymphocyte infiltration, endothelial dysfunc-
tion, and oxidative stress [2]. Interestingly, Itani et al. have
used a humanized mouse model in which the murine immune
system was replaced by the human immune cells. They ob-
served increased infiltration of human leukocytes, T cells, and
especially CD4+ subsets in thoracic lymph nodes, thoracic
aorta, and kidney in response to Ang II infusion. Also,
CD8+ infiltration was higher in both lymph nodes and thorac-
ic aorta in hypertensive animals compared with normotensive.
The increase in memory Tcells CD3+CD45RO+was noted in
the aortas and lymph nodes. In this model, human T cells
become activated and invade end-organ tissue, in response
to Angiotensin II stimuli [3].
The mechanisms of activation of adaptive immunity in hy-
pertension remain not fully defined. The role of the central
nervous system (CNS) in this process has been compellingly
demonstrated. It has been shown that the elevation in blood
pressure was eliminated by anteroventral third cerebral ventri-
cle (AV3V) lesions in mice. Also, the activation of circulating
Tcells and the vascular infiltration of leukocytes were reduced
in this model [37]. Recently, Carnevale et al. have
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demonstrated that splenectomized mice are protected from
Ang II–induced blood pressure increase. They found that
splenic placental growth factor (PIGF) is indispensable for
the onset of hypertension. The role of PIGF is repressing of
the expression of protein Timp3 (tissue inhibitor of metallo-
proteinases 3) involving the transcriptional Sirt1-p53 axis.
PIGF is essential for T cell co-stimulation via CD86. As a
result, the deployment of those cells towards vasculature and
target organs is observed [38•]. Splenectomized mice or mice
with left coeliac ganglionectomy were also unable to increase
blood pressure upon DOCA-salt challenge. The intact
neurosplenic sympathetic drive resulted in increased PIGF
expression in DOCA-salt mice. PIGF −/− mice subjected to
DOCA-salt model were protected from increased blood pres-
sure and Tcell co-stimulation and deployment towards kidney
[39]. Chronic high blood pressure is also associated with brain
damage and the development of neurodegenerative injury in
hypertensive individuals [40].
Seminal work by Kirabo et al. linked hypertensive oxida-
tive stress to the activation of adaptive immunity [13••]. It has
been well defined that hypertensive responses are also associ-
ated with an increase in oxidative stress [1••, 2, 41].
Superoxide production is increased due to increased NOX
activity, and this effect is associated with reduced NO produc-
tion and impaired endothelium–dependent vasodilatation [42].
Hypertension-induced oxidative stress can also affect vascular
smooth muscle cell function, which plays an important role in
contractility [43]. It has been shown that the pro-inflammatory
phenotype of SMC was essential to the development of pul-
monary hypertension [44]. Moreover, oxidative stress can af-
fect the proteins, which are next internalized by antigen-
presenting cells (APC). In multiple models of hypertension,
Kirabo et al. demonstrated that the proteins oxidatively mod-
ified by highly reactive gamma-ketoaldehydes (isoketals/
isolevuglandins) are formed and finally they are presented by
dendritic cells to T cells. After this contact, T cells become
activated and pro-inflammatory [13••]. Interestingly, the scav-
enging of isolevuglandins prevented experimental hyperten-
sion and may be the potential useful treatment strategy for this
disease [13••]. T cell activation requires receptor ligation and
co-stimulation. The second signal is supplied by the interac-
tion between CD80 and CD86 (B7.1 and B7.2, respectively)
on APC with co-receptor CD28 on T cells. Ang II–dependent
hypertension increased the content of CD86+ dendritic cells.
Interestingly, the blockade of B7-dependent co-stimulation
with CTLA-4-Ig reduced DOCA-salt and Ang II–induced hy-
pertension [45•]. CTLA-4-Ig abrogated activation of circulat-
ing T cells, cytokine production, and their vascular accumula-
tion [45•]. Deficiency in B7 ligands was accompanied bymin-
imal blood pressure elevation and vascular inflammation de-
spite Ang II infusion [45•]. Itani and colleagues have shown
that the formation of effectormemory T (T(EM)) cells requires
the co-stimulatory molecule CD70 on APC [17]. During a
murine N(omega)-nitro-L-argininemethyl ester hydrochloride
(L-NAME)/high-salt model of hypertension, T(EM) accumu-
lated in the kidney and produced IFN-γ and IL-17A. This
phenomenon is accompanied by an increased expression of
CD70 on macrophages and dendritic cells. CD70 deficiency
led to a lack of T(EM) accumulation and resulted in no devel-
opment of hypertension and renal damage [17]. The ablation
of myeloid CD11c+APC, participated in renal sodium trans-
port and prevented cardiac hypertrophy and the induction of
several indicators of renal and cardiac damage in response to
angiotensin II and high-salt diet [12]. APC were necessary for
the induction of intrarenal renin–angiotensin system compo-
nents and affected the modulation of natriuresis and tubular
sodium transporters [12]. The data provided by Shah et al.
revealed that myeloid-derived suppressor cells (MDSCs) play
an important role in attenuating hypertensive responses in dif-
ferent models including Ang II, L-NG-nitroarginine methyl
ester, and high salt. The depletion of MDSCs increased blood
pressure and renal inflammation [46]. Myeloid-derived sup-
pressor cells have an expression of markers and transcription
factors, which are associated with immunosuppression and
immaturity. Suppression of T cell activation was dependent
on hydrogen peroxide produced by MDSCs [46]. Recently,
we have shown that during Ang II–dependent hypertension,
the Sphingosine kinase 1 (Sphk1) was upregulated in the vas-
culature. This is important, taking into account the role of S1P
(sphingosine-1-phosphate) in the regulation of immune cell
trafficking. Chronic infusion (S1P) resulted in increased vaso-
constriction and endothelial dysfunction. Ang II–induced hy-
pertension was blunted in Sphk1−/− mice. In those animals,
decreased vasoconstriction was observed and enhanced endo-
thelial dysfunction suggesting the protective role of Sphk1 in
the endothelium [47].
Role of T Cells in Hypertension in Humans
Interestingly, the analysis of the T cell population from hyper-
tensive individuals revealed an increased percentage of
immunosenescence, pro-inflammatory, and cytotoxic CD8+
cells. These cells were characterized by the expression of
CD57 antigens and lack of expression of CD28 molecules
(CD8+CD57+CD28null). CD8+ cells derived from patients
with hypertension produced a higher level of perforin and
granzyme B in comparison with normotensive individuals.
Furthermore, hypertension was associated with a higher per-
centage of CD8+ T cells producing both IFN-γ and TNF-α.
This effect was not observed in CD4+ Tcells but in those cells
a higher percentage of perforin-positive cells was noticed in
hypertensive subjects in comparison with normotensive indi-
viduals. Renal tissue biopsies confirmed higher infiltration of
T cells and their subsets CD4+ and CD8+ in patients with
hypertensive nephrosclerosis [48]. Interestingly, this phenom-
enon was accompanied by an increased level of CHCR3
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chemokines (monokine induced by γ IFN (MIG), IFN-γ-
induced protein 10 (IP-10), and interferon-inducible T cell
alpha chemoattractant (I-TAC)), which are known to play a
role in pro-inflammatory T cell tissue homing [48].
Immunosenescence T cells appear as a consequence of repeat-
ed antigenic stimulation, and they are associatedwith age [11].
In hypertensive individuals, also the increase percentage of
CD45RO both CD4+ and CD8+ T cell subsets was observed
[3]. This finding of increased circulating memory T cells pro-
vides evidence of the activation of the immune system and
might have pathophysiological significance for sustaining hy-
pertension in humans. This observation was also accompanied
by an elevated level of RANTES chemokine in the plasma. In
a human cohort of subjects with metabolic syndrome and
other risk factors for coronary disease, we observed a signif-
icant inverse correlation between circulating RANTES level
and vascular function measured as flow-mediated dilatation
(FMD). In line with this, we found the positive correlation
between the biochemical marker for endothelial dysfunction,
von Willebrand factor (vWF), and RANTES level [2].
Sex Differences in T Cells–Mediated Hypertension
The majority of studies regarding the role of T cells in the
pathogenesis of hypertension have been performed in male
mice. However, both men and women develop hypertension.
There is increasing evidence that although Tcells also mediate
blood pressure development in females, there are differences
in T cell profile [49]. Ji et al. have suggested that the progres-
sion of renal disease and end-organ damage is faster in men
compared with women [50]. In this study, the authors showed
tha t the markers of rena l in jury, inc luding the
glomerulosclerosis index, mean glomerular volume, and pro-
teinuria, were greater in the renal wrap model of hypertension
in males compared with females. Also, endothelial NO syn-
thase expression was elevated in males and no differences
were noted in eNOS level in females with hypertension.
Interestingly, the eNOS was significantly decreased in male
medulla but not in the cortex and no differences were ob-
served in females in both renal compartments. Despite the
similar degree of hypertension in both males and females,
the renal function was dependent on gender [50]. In another
study, it has been shown using radio-telemetry that male SHRs
have a greater blood pressure than female [51]. The gonadec-
tomy decreased blood pressure in males and had no effect on
blood pressure in females. Greater plasma Ang II level was
observed in females and similar levels of renal cortical Ang II
in comparison with males. Interestingly, females had lower
expression of AT(1) receptor in the renal cortex, decreased
macrophage infiltration, and decreased oxidative stress which
was consistent with lower blood pressure [51]. This is inter-
esting because women more often than men develop inflam-
matory and autoimmune disorders (e.g., rheumatoid arthritis
(RA) and systemic lupus erythematous (SLE)), which are as-
sociated with an increased risk of cardiovascular diseases
[52–54]. Additionally, in the pathogenesis of preeclampsia,
the immune system plays an important role. Especially, this
disorder is associated with an increase in Th17 lymphocytes,
shift towards Th1 responses, and a decrease in Treg activity
both in humans and in the rat model of preeclampsia [55, 56].
Tipton et al. have demonstrated that spontaneously hyperten-
sive female rats had greater renal anti-inflammatory T lym-
phocyte infiltration than males who had greater CD4+ and
Th17 infiltration [23]. Males revealed higher blood pressure
than females, who had greater sensitivity to mycophenolate
mofetil–induced decrease in lymphocyte counts [23].
Interestingly, the administration of hydrochlorothiazide and
reserpine decreased T regulatory cells content only in female
SHR abolishing sex differences. This treatment had minimal
impact on Th17 cells. To assess the impact of sex hormones to
renal immune profile, the gonadectomy was performed.
Increased pro-inflammatory markers were observed after go-
nadectomy providing the suggestion that hormones play anti-
inflammatory roles in both males and females [57•]. Brinson
et al. have demonstrated that the administration of the nitric
oxide synthase (NOS) inhibitor (L-NAME) increases blood
pressure in both sexes; however, females exhibited a greater
increase in BP than males. L-NAME-induced hypertension
was associated with increased renal T cell infiltration with a
greater increase in Th17 cells and a greater decrease in Tregs
in female SHR in comparison with male. Interestingly, anti-
hypertensive therapy significantly reduced the L-NAME-
induced increase in renal T cell infiltration in both sexes.
This data suggests that NOS is essential in females SHR to
maintain BP and limit a pro-inflammatory renal T cell profile
in comparison with males [58]. Tregs can be responsible for
lower blood pressure in females in comparison with males.
Female mice are also protected against high-fat-diet-induced
metabolic syndrome. There was an increase in regulatory T
cell population in adipose tissue in response to weight gain in
females, which was opposite to the phenomenon observed in
males. High-fat-diet-fed males developed in this time adipose
t i s sue i n f l ammat ion , g lucose in to l e r ance , and
hyperinsulinemia [59].
Ji et al. have provided evidence that the signaling of pro-
and anti-inflammatory cytokines differ between the sexes
[60]. Sex differences in mean arterial pressure observed in
wild type mice, with higher pressure in males, were lost in
both sexes in RAG1−/− mice. Blood pressure was higher after
the adoptive transfer of male CD3 in comparison with female
CD3 into male RAG1−/−. RAG1−/−male with male CD3 had a
higher percentage of splenic IL-17A and TNF-α T cells and
lower plasma of IL-10. RAG1−/− male with female CD3 re-
vealed higher activation and Th1 response in renal inflamma-
tion. Greater T cell infiltration into perivascular adipose tissue
and kidney was associated with male but not female T cell
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donor [60]. Pollow et al. using the same model of Ang II–
infused RAG1−/− mice demonstrated that systolic blood pres-
sure responses were similar between sexes. Adoptive transfer
of male T cells was associated with higher blood pressure in
males when compared with females following Ang II infu-
sion. Renal T cell infiltration was significantly increased in
males compared with females in control and Ang II–infused
mice. This study provided evidence that female RAG1−/− an-
imals are protected from male T cell–mediated increases in
hypertension when compared with male knockouts.
Sex difference involves the infiltration of T cell especially
in both the kidney and the brain [61]. Recently, Sandberg et al.
have shown that CD4+ and CD8+ T cell subsets are different
in males and females and sex-specific effects of these cells
determine the magnitude of Ang II–induced hypertension
[62]. Interestingly, the adoptive transfer of both male CD4+
and CD8+ to male RAG1−/− resulted in greater mean arterial
pressure in response to Ang II compared with females derived
both CD4+ and CD8+ T cells [62]. Female CD8+ T cells
attenuated Ang II–induced hypertension compared with male
RAG1−/− mice. Only animals receiving male T cells exhibited
T cell infiltration into the subfornical organ. This is consistent
with the findings that 17β-estradiol acting via ERs in the SFO
inhibiting inflammatory process induced by Ang II especially
ROS production [63, 64].
The infiltration of renal FoxP3+CD4+CD3+ T cells was
higher in female SHR than that in male in 13-week-old ani-
mals. This effect was accompanied by a decreased frequency
of ROR-γ+CD4+CD3+ cells. Interestingly, no differences be-
tween females and males were noted in 5 weeks of age [65].
Schneider et al. demonstrated that sex could be associated
with the degree to which HLA propagate the selection and
further expansion of T cells characterizing T cell receptor var-
iable beta chain (TCRBV). Interestingly, immunosequencing
of 824 individuals revealed that HLA-associated shaping of
TCRBV differed between sexes. CD8 T cells in men with
autoimmune disease were capable to expand even without
expressing TCRBV with similarity in pivotal HLA-binding
regions [66].
Role of B Cells and Their Antibodies in Hypertension
As a concept of the central role of T cell in hypertension is
widely accepted, the role of B cells is not as evident. However,
Chan and then subsequently Dingwell provided compelling
evidence for the B lymphocyte role in hypertension. Ang II–
dependent hypertensive responses were attenuated in B cell-
activating factor receptor-deficient (BAFF-R−/−) mice, lacking
mature B cells. Interestingly, the transfer of B cells to those
animals restored blood pressure increase. BAFF-R −/− was
associated with reduced IgG accumulation and macrophage
content in the aorta. Those animals were also protected from
collagen deposition and aortic stiffening induced by Ang II.
The protection from hypertension was also conveyed by the
administration of anti-CD20 antibody providing proof of con-
cept for future therapeutic use [67]. Dingwell et al. confirmed
that B cell deficiency resulted in lower blood pressure in mice
[68]. Mice homozygous for proto-oncogene c-myb had re-
duced B220+ B cells in peripheral blood and kidney and re-
vealed decreased both systolic and diastolic blood pressure
compared with WT animals. Interestingly, those animals had
lower susceptibility to DOCA-salt experimental hypertension.
Reconstitution ofWTmice with bone marrow transplant lack-
ing B cells resulted in decreased blood pressure [68]. This
effect was associated with reduced vasopressin receptor 2
(V2R) in the kidney [68].
These data correspond to findings of the role of elevated
autoantibody levels in both experimental models of hyperten-
sion and in humans. Wu et al. demonstrated that there is an
association of antibodies against heat shock protein 70
(Hsp70) with hypertension. The presence of antibodies to
Hsp70 was higher in subjects with a blood pressure of 160/
95 mmHg than that in those with a blood pressure of 140/
90 mmHg [69]. In another study, it has been shown that the
level of antibodies against Hsp70 and Hsp65 is elevated in
hypertension in comparison with normotensive individuals
but no changes in Hsp60, Hsp70, and anti-Hsp60 levels were
observed [70]. However, the study performed in patients with
coronary heart disease revealed that high concentration of
anti-Hsp60 antibodies was elevated in comparison with the
controls. Increasing concentration of anti-Hsp60 was associ-
ated with a higher risk of CHD, hypertension, and diabetes
[71]. Autoantibodies against angiotensin II receptor type 1
(AT1) have been discussed in relation to their role in hyper-
tension for a long time. Their increased levels were found in
patients with preeclampsia [72]. Levels of anti-AT1 correlated
with the severity of this disease [73]. Also, in malignant hy-
pertension, there was an increased level of autoantibodies
against AT1 but not AT2 receptors [74]. Zhu et al. have
showed that autoantibodies against AT1 in patients with es-
sential hypertension correlated with the polymorphism of
HLA-DRB1 [75]. Liao et al. have demonstrated that in pa-
tients with refractory hypertension there is a higher frequency
of autoantibodies against AT1-receptor and alpha1-adrenergic
receptor (α1-AR) [76]. The elevated level of antibodies
against α1-AR in both primary and malignant hypertension
has been conf i rmed in o the r s tud i e s [77 , 78 ] .
Immunoadsorption of α1-AR antibodies resulted in blood
pressure reduction in patients with refractory hypertension.
These antibodies induced signaling pathways involving pro-
tein kinase C alpha activation and ERK1/2 phosphorylation,
which are important for hypertension and cardiac remodeling
[79]. The presence of autoantibodies has been also observed in
sera of spontaneously hypertensive rats [80]. Interestingly,
sera of SHR contained autoantibodies against both beta 1-
adrenoceptor and arterial antigens indicating B lymphocyte
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involvement in a genetic model of essential hypertension [80,
81]. The role of such antibodies may also be important for
target organ damage. Autoimmune reactions to cardiac
beta1-adrenergic receptor plays a causal role in dilated cardio-
myopathy in an animal model [82]. Interestingly, in patients
with hypertension, autoantibodies against cardiovascular L-
type Ca2+ channels have been commonly found, especially
in patients with comorbidities such as coronary heart disease
and left ventricular diastolic dysfunction [83].
Role of Cytokines Involved in Adaptive Immunity
in Hypertension
T cell–derived cytokines play a central role in the pathophys-
iology of cardiovascular disease and hypertension and con-
tribute to the end-organ damage [1••, 7, 84]. One of the first
identified and best-characterized cytokines in relation to hy-
pertension is IL-17. T helper 17 (Th17) cells and their pro-
inflammatory cytokine IL-17 play an essential role in hyper-
tensive autoimmune diseases and endothelial dysfunction [85,
86•]. IL-17 increases blood pressure and decreases NO-
dependent relaxation responses by activation of RhoA/Rho-
kinase. Moreover, the inhibition of Rho-kinase prevented hy-
pertension caused by IL-17 [85]. Interestingly, the vessels
from IL-17−/− mice displayed preserved vascular function
and decreased superoxide anion production. This effect was
accompanied by a significant reduction in T cell infiltration in
response to chronic Ang II infusion [86•]. IL-17 together with
TNF modulated the expression of over 30 genes including
inflammatory cytokines in human aortic smooth muscle cells
[86•]. The murine and human Th17 is induced by sodium
chloride in vivo. High-salt concentrations activate the p38/
MAPK pathway involving a nuclear factor of activated T cells
5 (NFAT5) and serum/glucocorticoid-regulated kinase 1
(SGK1) [87]. This kinase is critical for regulating IL-23R
expression by deactivating a direct repressor of this receptor
(Foxo1) and stabilizing Th17 phenotype [88••]. Modest in-
crease in salt concentration induces SGK1 expression, pro-
motes IL-23R expression, and enhances Th17 differentiation
[88••]. Ang II–dependent hypertension was associated with an
increased percentage of both IL17+CD4+ T cells and IL17+
CD3+CD4−CD8− T cells in perivascular adipose tissue. The
main producers of IL-17 were CD3+CD4−CD8− T lympho-
cytes [2, 41]. Recently, Saleh et al. provided the evidence that
the primary Tcell subsets producing IL-17A in the kidney and
aorta are γδ T cells and CD4+ T helper 17 cells. Additionally,
they found that antibodies against IL-17A or the IL-17 recep-
tor A subunit (IL-17RA) lowered blood pressure and attenu-
ated renal and vascular lymphocyte infiltration in Ang II–
infused animals. This phenomenon was not observed when
IL-17F antibodies were administered. Interestingly, IL-17A
or IL-17RA antibodies reduced transforming growth factor
beta (TGF- β) levels compared with control IgG1 antibodies
[89]. IL-17A regulates renal sodium transporters [90, 91].
During Ang II–dependent hypertension, IL-17A together with
IFN-γ interferes with the pressure natriuretic decrease in prox-
imal tubule sodium transporters [90]. IL-17A−/− abolished the
activation of distal tubule transporters, specifically the sodium
chloride co-transporter and the epithelial sodium channel and
protected mice from glomerular and tubular injury [91].
Interestingly, the single dose of Ang II initiated neuronal and
immune cell activity and affected circulating levels of CD4+
IL-17+ T cells and increased IL-17 levels in WKY rats [92].
These changes are essential in the developing of hypertensive
phenotype in WKY rats [92]. Recently, Wang and colleagues
have shown that the deficiency in P-selectin glycoprotein
ligand-1 was associated with reduced blood pressure upon
Ang II infusion. Interestingly, this effect resulted in reduced
plasma IL-17 level in Psgl-1−/−mice compared with wild type
(WT) animals. The administration of recombinant IL-17 re-
stored the reduced response to Ang II [93]. IL-17 expression is
regulated by Tri-partite motif (TRIM) 21 [94]. The lack of
TRIM21in Ldlr−/− mice resulted in elevated CD4+ T cells in
the periphery and increased IL-17 mRNA expression in
plaque suggesting that this molecule is a regulator of tissue
inflammation and pro-inflammatory cytokine production [94].
In humans, the serum level of IL-17 was significantly in-
creased in hypertensive subjects compared with normotensive
individuals [86•]. Yao et al. have further confirmed that serum
concentration of IL-17 was significantly increased in
prehypertensive subjects in comparison with optimal blood
pressure individuals and elevated level of this pro-
inflammatory cytokine was accompanied by a rise in systolic
blood pressure [95]. Especially, CD4+ T cells of humans with
hypertension produced higher amounts of IL-17A than nor-
motensive controls [3].
Interestingly, prolonged hypertension influences IL-17A
serum levels and anti-hypertensive diuretic treatment was as-
sociated with higher IL-17A concentrations suggesting that
arterial hypertension stimulates immune response indepen-
dently of the blood pressure regulation [96]. Other well de-
fined adaptive immunity cytokines in hypertension include
IFN-γ and TNF-α. In the experimental model of hypertension
and in human hypertensive individuals, the pivotal role of
IFN-γ was confirmed. Marko et al. have demonstrated that
IFN-γ plays an important role in experimental Ang II–
dependent hypertension. IFN-γR−/−mice had reduced cardiac
hypertrophy and reduced cardiac infiltration of both macro-
phage and T cell and less fibrosis in comparison with WT
upon Ang II administration [97]. IFN-γR deficiency was as-
sociated with reduced inflammation and improved glomerular
infiltration rate in the kidney and increased albuminuria in
comparison with the control animals [97]. IFN-γ deficiency
resulted in blunted hypertension in response to Ang II infu-
sion. Increased number of IFN-γ+CD8+ T cells in the spleen
and kidneys of Lnk−/− mice compared with WT mice was
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observed upon Ang II administration [36]. Our results con-
firmed that IFN-γ plays an important role in experimental
hypertension. Angiotensin II increased the expression of
mRNA encoding IFN-γ in perivascular adipose tissue [2]. A
small number of CD8+ T cells produced this cytokine at the
baseline and chronic Ang II infusion increased the content of
IFN-γ+CD8+ lymphocytes in perivascular adipose tissue [2,
41]. Double-negative T cells produced significant amounts of
IFN-γ in Ang II–infused mice, but this production was lower
in comparison with CD8+ T cells. Interestingly, we observed
that the incubation of the aorta with IFN-γ caused endothelial
dysfunction. This effect was partially reversed by pre-
incubation of the vessel with PEG-SOD [2]. CD8+ T cells
produced higher amounts of IFN-γ in patients with hyperten-
sion in comparison with normotensive controls [3].
The hypertensive responses are also aggravated by TNF.
Despite that TNF-α inhibitor etanerecept had no effect on
arterial blood pressure in DOCA-salt hypertensive rats, it
lowered both the proteinuria and cortical NF-κB activity
[98]. Interestingly, using TNF-α−/− mice, Sriramula et al.
showed that Ang II–induced increase in arterial pressure in
WT mice was absent in knockout animals. Also, cardiac hy-
pertrophy was attenuated in TNF-α−/− mice and the therapy
with recombinant TNF restored all responses induced by Ang
II in WT [99]. TNF−/− mice had blunted hypertensive re-
sponses and reduced end-organ damage in a model of chronic
kidney disease. This effect was associated with augmented
eNOS expression in the kidney and enhanced NO bioavail-
ability in TNF-lacking animals [100]. TNF-alpha in the kid-
ney contributed to the development of hypertension and renal
injury in Dahl salt-sensitive (SS) rats [101]. Intrarenal TNF-α
increased by high-salt diet in Dahl SS rats, and etanerecept
administration improved renal damage and hypertension
[101]. In rats with renovascular hypertension, the injection
of TNFR1 neutralizing antibody returned blood pressure to
normotensive level. Interestingly, TNF-alpha administration
into normotensive rats increased blood pressure and sympa-
thetic nerve activity predominantly to the heart. TNFR1 neu-
tralizing antibody abolished this effect [102]. Recently, we
have shown that the percentage of both CD4+TNF+ and
CD8+TNF+ T cells in perivascular adipose tissue was higher
in Ang II–dependent hypertension in comparison with control
animals. This was also true for TNF+CD3+CD4−CD8− T
cells [41]. Anti-inflammatory interventions decreased the per-
centage of TNF+CD8+ T cells and did not affect other exam-
ined subsets [41].
While the pro-inflammatory cytokines such as IL-17,
IFN-γ, and TNF-α have a detrimental effect in the pathogen-
esis of hypertension, the role of anti-inflammatory IL-10 is
protective. Didion et al. have demonstrated that the systemic
administration of Ang II resulted in marked impairment of
endothelial function in IL-10−/− mice in comparison with
WT despite the similar increases in arterial blood pressure.
Endogenous IL-10 limited Ang II–mediated oxidative stress
and superoxide scavenging in IL-10−/− mice improved vascu-
lar function [103]. Moreover, the treatment of hypertensive
mice with IL-10 reduced both systolic blood pressure and
activity of NADPH oxidases. Also, improved endothelial
function in mesenteric resistance artery was observed in com-
parison with untreated hypertensive animals [104]. IL-10 in-
fusion prevented the blood pressure increase and vascular
dysfunction in Ang II–infused WT mice. This effect was as-
sociated with the modulatory role of IL-10 to limit of
RhoA/Rho-kinase signaling pathway [105]. Barhoumi at el.
provided evidence that hypertension is associated with re-
duced T regulatory cells numbers [106•]. The adoptive trans-
fer of CD4+CD25+ Treg subsets but not CD4+CD25− T ef-
fector cells suppressed Ang II–mediated vascular injury in
part through anti-inflammatory actions [106•]. Another study
performed byMatrougui et al. revealed that Tregs are essential
in the development of coronary arteriolar endothelial dysfunc-
tion in hypertension. The injection of Tregs from control mice
to hypertensive animals reduced TNF-α release and improved
endothelium-dependent relaxation [107]. The transfer of
Tregs caused improved cardiac hypertrophy and less cardiac
fibrosis but did not prevent an increase in blood pressure in
mice. In this study, the reduction of CD4+, CD8+, and CD69+
cells and macrophage in the heart was noticed [108]. Also, in
experimental preeclampsia, IL-10 administration normalized
blood pressure and endothelial function. This effect was me-
diated by decreased plasma levels of endothelin-1, circulating
and placental IFN-γ, and aortic and placental PECAM [109].
Anti-hypertensive effect of IL-10, in both the thoracic aorta
and VSMCmanifested in decreased systolic blood pressure in
SHR, is mediated by CCL5 [110]. Interestingly, the serum
levels of IL-10 and FoxP3 mRNA expression and the percent-
age of Treg (CD4+CD25+) were decreased in pregnancy-
induced hypertensive (PIH) patients. At the same time, a sig-
nificant increase of PD-1 in Treg was found in PIH compared
with normal pregnancy. The PD-ligand 1 Fc increased Treg
number and elevated TGF-β and IL-10 expression. The
blocking of PD-L1 by using monoclonal antibody reversed
this effect [111]. The suppression of Treg can be modulated
by Nox2 [112]. Nox2 deficiency increased the number of Treg
in the heart at the baseline, and Ang II inhibited the infiltration
of effector T cells (Teff). Mice with Nox2 deficiency in CD4+
Tcells showed inhibition of Ang II–induced hypertension and
cardiac remodeling due to increased Treg and reduction in
Th17 content. This protective effect was reversed by anti-
CD25 antibody [112].
In Ang II–dependent hypertension, there is an imbalance
between Th17/Treg in the spleen and in renal/cardiac infiltrat-
ing lymphocytes resulting in increased expressions of IL-17A,
IL-23, and TNF-α, and decreased expression of IL-10. This
imbalance in Th17/Treg in Ang II–induced hypertension is
caused by serum/glucocorticoid-regulated kinase 1 (SGK1)
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[113]. Using of EMD638683-SGK1 inhibitor reversed cardiac
and renal dysfunction induced by Ang II [113]. Also, the
mechanism of the microvascular dysfunction in mice with
established hypertension is associated with depletion in Treg
[114]. In hypertensive mice, Treg displayed enhanced apopto-
sis and increased autophagy inmesenteric artery. Interestingly,
the inhibition of autophagy or transfer of Treg into mice with
establishes hypertension improved microvascular function
[114].
Conclusion
Adaptive immune responses, both T cell and B cell mediated,
play a pivotal role in the development of hypertension and in
mediating target organ damage. Adaptive immunity activation
of both T cells and B cells is initiated early in the course of the
disease and greatly contributes to important pathogenetic
changes, through release of pro-inflammatory cytokines and
antibodies. This leads to changes of renal sodium transporter
expression and vascular endothelial as well as cardiac, renal,
and perivascular fibrosis. While these mechanisms have been
well defined in animal models, less evidence is available in
humans. Unquestionably, such a large body of evidence war-
rants the development of novel anti-hypertensive strategies
targeting adaptive immunity hypertensive mechanisms.
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